

Voglibose Improves Endothelial Function in Patients with Type 2 Diabetes.

Nakamura K, et al. Cardiovasc Diabetol. 2014; 13:110.

- Alpha glucosidase inhibitors (i.e., voglibose) attenuate postprandial hyperglycemia (PPH) and reduce the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes.
- In a randomized, multicenter study in 35 type 2 diabetics who did not achieve treatment goal with sulfonylurea, metformin or pioglitazone, voglibose therapy significantly improved flow-mediated dilatation (FMD) of the brachial artery after 12 weeks of treatment.
- Mild, reversible GI side effects were occasionally reported.

**Voglibose improved endothelial dysfunction in patients
with type 2 diabetes.**